ClinicalTrials.gg
RecruitingNCT07938710Updated Nov 16, 2026

Incidence and Clinical Features of PHACE Syndrome

An observational study in PHACE Syndrome and Infantile Hemangioma (IH), sponsored by West China Hospital. Recruiting at 3 sites in China. Open to participants aged 0 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by West China Hospital · Observational

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3
Ages
0 Months to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hemangioma, Capillary with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Hemangioma, Capillary · China.

Started
2022
the only one that year
Observational
7 of 12
5 open now
Registered
11th of 12
by date
Lead sponsor
8 of 12
West China Hospital

Among the 12 studies in Hemangioma, Capillary with a site in China, this one is the only one that started in 2022, is one of 7 observational ones, and was the 11th registered.

Hemangioma, Capillary

35 studies on the registry are indexed under Hemangioma, Capillary; 6 are open to participants now.

Browse Hemangioma, Capillary studies →

Open to participants now

6 of the 12 studies in Hemangioma, Capillary with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 3 Hemangioma, Capillary studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 0 Months to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hemangioma, Capillary with a site in China, or all of them as a file.
02

Study summary

This study will include infants seen at three hospitals who have a segmental infantile hemangioma, a blood vessel growth affecting a broad area of skin. Eligible areas include the scalp, face, neck, upper chest or back, and shoulder or upper arm. The study will measure how often PHACE syndrome is found in infants with enough clinical information to determine the diagnosis. PHACE syndrome can involve differences in the development of the brain, arteries, heart, eyes, or the midline of the chest and abdomen. The study team will describe these findings and the hemangiomas. The treating clinicians will manage evaluation and care.

Read the detailed description

This prospective observational cohort will consecutively invite infants with a clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity at their first qualifying presentation to a participating center. Infants can enroll regardless of whether a PHACE evaluation or diagnosis is already documented. Prior evaluation and referral source will be recorded. Each infant will be enrolled once. A parent or legal guardian will provide written informed consent.

At enrollment, study clinicians will record age, sex, the anatomic distribution and laterality of the segmental lesions, the longest diameter of the largest qualifying lesion, and lesion depth. Photographs will be recorded when permitted by the protocol and consent. Each infant will be assigned to one anatomic stratum. The strata are head involvement with or without other sites, isolated neck, isolated upper trunk, isolated proximal upper extremity, and multiple sites without head involvement. All involved regions will also be recorded.

The study will collect clinical findings and results of clinically indicated assessments, including examination for ocular and ventral midline abnormalities, echocardiography, and magnetic resonance imaging and angiography of the head and neck, with aortic arch assessment. The treating team will determine which examinations and treatments are clinically appropriate. Prior assessments can contribute to classification when they meet the same protocol criteria for adequacy.

A central panel will apply the revised 2016 PHACE consensus diagnostic criteria. A hemangioma of the head, including the scalp, that exceeds 5 cm in diameter supports a diagnosis of definite PHACE when accompanied by at least one major or two minor criteria. For large segmental hemangiomas of the neck, upper trunk, or trunk with proximal upper-extremity involvement, definite PHACE requires at least two major criteria. Isolated proximal upper-extremity lesions will be described separately. Classification as definite PHACE will require documented fulfillment of the consensus criteria.

The primary analysis will include infants with a protocol-defined evaluable assessment by six months after enrollment. An evaluable assessment requires interpretable documentation of the prespecified core clinical, cardiac, and neurovascular evaluations, irrespective of the diagnostic classification. Definite PHACE, possible PHACE, and neither category will be reported separately. Inadequate evaluations will be recorded with the reason and retained in the enrollment count. The study will report the assessment completion proportion and the definite PHACE proportion with 95% confidence intervals overall and by anatomic stratum where estimable.

03

Conditions studied

  • PHACE Syndrome
  • Infantile Hemangioma (IH)

Keywords

  • Segmental Infantile Hemangioma, PHACE, Anatomic Distribution, Congenital Anomalies, Cohort
04

Who can participate

Ages eligible
0 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Infants from birth through 12 months of age at their first qualifying presentation during the recruitment period at one of the three participating centers, with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • From birth through 12 months of chronological age at enrollment.
  • Clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
  • First qualifying presentation at a participating center during the recruitment period.
  • Written from a parent or legal guardian.

Exclusion criteria

Exclusion Criteria

  • The lesion responsible for eligibility is subsequently adjudicated to be a different vascular anomaly, such as a congenital hemangioma or vascular malformation.
  • Prior enrollment in this study at any participating center.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Infants With Segmental Infantile Hemangiomas

    Infants with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity who are enrolled at one of the three participating centers.

06

What researchers measure

Primary outcomes

  1. Proportion of Evaluable Infants With PHACE Syndrome

    Percentage of infants with an evaluable PHACE assessment who fulfill the revised 2016 consensus criteria for PHACE. Evaluable assessments have the prespecified core clinical, cardiac, and neurovascular evaluations documented and interpretable. Each infant is counted once.

    Time frame: At enrollment through 6 months after enrollment.

Secondary outcomes

  1. Anatomic Distribution and Laterality of Segmental Hemangiomas

    Number and percentage of infants by involved anatomic region and lesion laterality (left, right, bilateral, or midline) among infants with evaluable lesion documentation.

    Time frame: At enrollment.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, Maguiness S, Mancini AJ, McCuaig C, Metry DW, Morel K, Powell J, Perkins SM, Siegel D, Drolet BA. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010 Aug;126(2):e418-26. doi: 10.1542/peds.2009-3166. Epub 2010 Jul 19. PubMed 20643720 ↗
  • Garzon MC, Epstein LG, Heyer GL, Frommelt PC, Orbach DB, Baylis AL, Blei F, Burrows PE, Chamlin SL, Chun RH, Hess CP, Joachim S, Johnson K, Kim W, Liang MG, Maheshwari M, McCoy GN, Metry DW, Monrad PA, Pope E, Powell J, Shwayder TA, Siegel DH, Tollefson MM, Vadivelu S, Lew SM, Frieden IJ, Drolet BA. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016 Nov;178:24-33.e2. doi: 10.1016/j.jpeds.2016.07.054. Epub 2016 Sep 19. No abstract available. PubMed 27659028 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Mar 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Apr 1, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938710
Collaborators
West China Second University Hospital, Children's Hospital of Fudan University
Responsible party
Yi Ji (Doctor, West China Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Apr 1, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Yi Ji Ji, PhD
Contact
jijiyuanyuan@163.com
02885423453

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion